Novocure: Using Electrical Fields as a Fourth Cancer Treatment Modality

Executive overview

Cancer treatment has relied on three modalities for over 120 years: surgery, radiation, and chemotherapy. All three are limited by toxicity — they harm healthy tissue alongside cancer cells, capping effective dose.

Novocure's tumor treating fields (TTFields) use alternating electrical fields tuned to specific frequencies to disrupt cell division in cancer cells. Because cancer cells and healthy cells differ in membrane properties, the fields can be targeted selectively. The therapy has no meaningful toxicity, enabling continuous use alongside existing treatments.

The core insight: a physics-based therapy can overcome the toxicity ceiling that limits every existing cancer treatment.

The three legacy modalities and their shared flaw

• Surgery is most effective when cancer is caught early and localized — curative if removed completely
• Radiation kills dividing cells via ionizing energy; dose is capped by damage to surrounding healthy tissue
• Chemotherapy delivers targeted poisons; side effects limit dose, almost always leaving residual disease
• Immunotherapy aims to unmask cancer cells so the immune system attacks them; most patients still don't respond
• All legacy approaches share the same constraint: toxicity limits the dose before the cancer is fully eliminated

How tumor treating fields work

• Cancer cells divide rapidly; the proteins driving division carry strong electrical charges (dipoles)
• An alternating electric field at the right frequency pushes and pulls those proteins, killing the cell during division
• Cell membranes filter electric fields — frequency must be tuned to penetrate cancer cells specifically
• Different cancers require different frequencies, analogous to tuning an FM radio to a specific station
• Healthy non-dividing cells are largely unaffected; the therapy has no systemic toxicity

The device and delivery model

• Patients wear a portable device (~1 kg) connected to adhesive antenna arrays placed on the skin over the tumor site
• For brain cancer: arrays are placed on a shaved head; for lung cancer: on the torso
• Device runs continuously; patients take breaks only for showers and exercise
• Battery technology follows automotive advances (same cells as Tesla); device will continue to shrink
• 24/7 patient support is provided directly by Novocure — no hospital intermediary

Clinical results in glioblastoma (GBM)

• GBM affects ~15,000 US patients per year; median age late 50s; effectively a death sentence
• Over 35 phase three drug trials have failed in GBM
• Standard-of-care control group in Novocure's trial: 5% five-year survival
• Adding TTFields to standard care: 13% five-year survival — roughly tripling the rate
• Patients using TTFields more than 20 hours per day: 30% five-year survival
• Strong dose-response relationship: the therapy works when on, stops working when off
• Results published in JAMA; TTFields rated NCCN Category 1 (standard of care) for GBM

Expansion pipeline

• FDA-approved for GBM (2015); also approved in Europe, Japan, and China
• Phase 3 trials near completion or underway: non-small cell lung cancer (~200,000 US cases/year), ovarian (~40,000), pancreatic (~40,000)
• Partnerships with Merck (lung cancer) and Roche/Genentech (pancreatic cancer)
• Same mechanism of action has shown effect across 20–30 cancer cell lines and every animal model tested
• Geographic expansion underway: beyond US, Germany, and Japan into rest of Europe, Canada, Australia, Asia-Pacific

Business model and financials

• Revenue ~$500M; gross margins ~80%; no equity raised since 2015 IPO
• Subscription model: monthly fee per patient, billed directly to payers — no hospital distributor middlemen
• Fee is priced comparably to high-end pharmacological therapies
• ~40% of eligible US GBM patients currently receive a prescription; 60% remain to be captured
• Small, education-focused sales force (~50 US reps vs. 300–400 for typical pharma/ortho)
• Capital-light: no large factories; leverages global medtech supply chain

Competitive moats

• 180+ global patents on fundamental mechanisms, not incremental features
• Any competitor would need to run their own multi-year, $100M+ phase 3 cancer trials for regulatory approval
• No competitor has entered the space since founding
• Engineering roadmap: next-generation arrays will increase dose by solving the skin-temperature heat dissipation limit
• R&D spend will trend toward medtech levels (5–7% of revenue) rather than biotech (20–25%) because the mechanism is proven — expansion is clinical development, not discovery

Adoption barriers and outlook

• Only ~40% of eligible GBM patients currently receive TTFields; educational gap among oncologists is the primary obstacle
• Oncologists trained in biology, not physics; a physics-based therapy requires re-framing
• Healthcare system is structurally conservative — hospital systems, payers, and clinicians move slowly
• Next generation of oncologists will study TTFields in medical school
• Bears focus on timing of expansion (COVID slowed trial enrollment), not on whether expansion will occur

Lessons from building Novocure

• Transformational healthcare innovation takes decades, not years; Novocure is 21 years in
• $500M raised before reaching breakeven — realistic capital planning is essential
• Institutional resistance to new modalities is structural, not personal; persistence is the only path
• A true long-term partner (CEO Asaf Danziger, 20-year collaboration) is non-negotiable for this type of venture